CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis

Immunopharmacology and Immunotoxicology
Fatemeh SafariAva Nasrolahi

Abstract

Rheumatoid arthritis (RA), as one of the most disabling autoimmune diseases, is a common health problem that progressively reduces the life quality of patients. Although various biologics have been introduced for RA, attempts to establish an efficient long-term therapies failed due to the heterogeneity of this disease. In the last decade, immunomodulatory approaches such as T cell adoptive therapy have been developed for controlling autoimmunity. Regulatory T cells (Tregs), the major self-tolerance mediator, are crucial for down-regulation of aberrant immune stimulations. Hence, recruiting ex vivo Tregs emerged as a promising therapy for a variety of autoimmune diseases. The major bottleneck of the Treg adoptive therapy is maintaining the in vivo stability and plasticity of these fascinating cells. Recent progress in genome editing technology clustered regularly interspaced short palindromic repeats (CRISPR) in combination with CRISPR-associated (Cas) 9 system provided a new solution for this bottleneck. The present paper discusses RA pathogenesis and the potential application of new developments in CRISPR-mediated Treg genome editing in personalized therapy of RA.

References

Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·A E SchröderC Berek
Jun 1, 1996·The Journal of Experimental Medicine·T L WalunasJ A Bluestone
Feb 27, 2001·Journal of Immunological Methods·Z EshharD G Schindler
Jul 17, 2001·Annals of the Rheumatic Diseases·M CutoloR H Straub
Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
May 16, 2003·Nature·Gary S Firestein
Jul 10, 2003·Autoimmunity Reviews·M A M van Boekel, W J van Venrooij
Dec 15, 1954·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·R E BILLINGHAMP B MEDAWAR
Oct 28, 2003·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Erik R VossenaarGer J M Pruijn
May 15, 2004·Arthritis Research & Therapy·Erik R Vossenaar, Walther J van Venrooij
Jul 29, 2004·The Journal of Experimental Medicine·Michael R EhrensteinClaudia Mauri
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Junko OhataThomas J Kipps
Mar 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sigrid E SandnerMohamed H Sayegh
Jun 30, 2005·Arthritis and Rheumatism·Mary E MorganRené E M Toes
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoshihiro MiyaharaHiroshi Shiku
Dec 24, 2005·The New England Journal of Medicine·Franck PagèsJérôme Galon
Mar 16, 2006·Blood·Xavier ValenciaPeter E Lipsky
Sep 29, 2006·Rheumatology International·Niko K BenderBernhard Heilig
Dec 8, 2007·Annals of the Rheumatic Diseases·H YamadaY Yoshikai
Mar 21, 2008·Nature Reviews. Cancer·Steven A RosenbergMark E Dudley
Apr 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bitao LiangRaphael Clynes
Aug 7, 2008·Pharmacogenomics·Maria I DanilaS Louis Bridges
Nov 28, 2008·Proceedings of the National Academy of Sciences of the United States of America·Fabian Flores-BorjaMichael R Ehrenstein
Apr 8, 2009·European Journal of Immunology·Leigh A StephensStephen M Anderton
Oct 3, 2009·Nature Reviews. Rheumatology·Ann L CornishIan P Wicks
Nov 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Graham P WrightHans J Stauss
Nov 4, 2009·Nature Reviews. Rheumatology·Hiroshi Takayanagi
Jan 19, 2010·Journal of Autoimmunity·Gabriel J TobónAlain Saraux
Mar 2, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Louise A SwainsonJoseph M McCune
Mar 27, 2010·Science·Alexandra Zanin-ZhorovMichael L Dustin
Jun 16, 2010·The Journal of Experimental Medicine·Shahin ShafianiKevin B Urdahl
Jun 19, 2010·Nature Reviews. Immunology·Shimon SakaguchiDavid A Hafler

❮ Previous
Next ❯

Citations

Apr 17, 2018·Human Molecular Genetics·Cui ZhangJinfu Wang
Oct 15, 2018·Journal of Cellular Physiology·Vahideh TarhrizShirin Eyvazi
Feb 24, 2019·Reviews in the Neurosciences·Ava NasrolahiJavad Mahmoudi
Oct 19, 2019·International Reviews of Immunology·Juan Esteban Garcia-RobledoGabriel J Tobón
Jun 21, 2019·Journal of Cellular Biochemistry·Vahideh AhmadzadehHabib Zarredar
May 16, 2019·Cell & Bioscience·Fatemeh SafariYounes Ghasemi
Aug 16, 2019·Applied Microbiology and Biotechnology·Leila RahbarniaSayna Toraby
Dec 12, 2019·Journal of Gastrointestinal Cancer·Dariush ShanehbandiMajid Khalili
Nov 29, 2020·Endocrine Reviews·Braulio A Marfil-GarzaA M James Shapiro
Dec 17, 2019·Cell Metabolism·Jeremy T WarshauerMark S Anderson
Nov 15, 2020·Biological Research·Fatemeh SafariHesam Dehghani
Jan 12, 2021·Virus Research·Fatemeh SafariAbbas Behzad-Behbahani
Apr 7, 2021·Acta Biomaterialia·Molly KlimakFarshid Guilak
Apr 20, 2021·Frontiers in Immunology·Qi JiangDawei Cui
Jun 1, 2021·Frontiers in Pharmacology·Pan Lin XinCheng Wen Dan
Aug 9, 2020·Aging and Disease·Allen CaobiNazira El-Hage

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.